A purple and pink letter v on a white background.
October 10, 2019

DiamondPolar™ Applicator Featured in Tweak of The Week

Author and influencer Alice Hart-Davis recently underwent a radio frequency wrinkle reduction treatment   using our DiamondPolar™ applicator on the Venus Versa™ multi-application medical aesthetic device . The treatment was documented in a video as well as in her blog, Tweak of the Week . The treatment was performed by skin care expert Teresa Tarmey , who explains the benefits of the technology.

“It’s a good option for people who don’t want anything invasive, or to have any injectables,” explains Tarmey, adding, “Also, you can focus treatment on the areas of the face where it is needed.”.

Hart-Davis, who also wrote  the book The Tweakments Guide: Fresher Face , had this to say about how she felt after the treatment: “When she sits me up at the end of the treatment, I can see the lift** that she has managed to generate in just half an hour. My cheekbones look better defined, as does my jawline. My face is a bit pink immediately after the treatment from the heat, but that calms down within an hour, leaving me with a healthy glow.”

The DiamondPolar™ applicator is designed for smaller treatment areas such as the face, jowls, and arms. In addition to Venus Versa™, it is also available on several of our other medical and aesthetic devices, including Venus Legacy™* and Venus Versa™*. The applicator is powered by Venus Concept’s proprietary (MP) technology, a synergistic combination of Multi-Polar Radio Frequency and Pulsed Electro Magnetic Fields.  

Radio frequency works to effectively heat and directly stimulate fibroblasts, while PEMF is known to promote angiogenesis and induce fibroblast proliferation through release of the growth factor FGF-2, resulting in increased collagen synthesis. Together as (MP) 2 , the two technologies work to reduce the appearance of fine lines and wrinkles, providing an effective solution for one of the top aesthetic concerns for patients.

Venus Concept offers a variety of different devices that provide non-invasive wrinkle reduction along with more today’s most in-demand aesthetic treatments. Click the button below to learn more about how you can add these medical and aesthetic devices to your practice.

* Venus Legacy™ is cleared by the FDA for the non-invasive treatment of moderate to severe facial wrinkles and rhytides in females with Fitzpatrick skin types I-IV with the OctiPolar™ and DiamondPolar™ applicators, and temporary reduction in the appearance of cellulite with the 4D Body (LB2) and 4D Face (LF2) applicators. It is licensed by Health Canada and has CE Mark for the temporary increase of skin tightening, temporary circumferential reduction, temporary cellulite reduction, and temporary wrinkle reduction.

* Venus Versa™ is cleared by the FDA, licensed by Health Canada, and has CE Mark as a multi-application device intended to be used in aesthetic and cosmetic procedures. The SR515 and SR580 applicators are cleared by the FDA, licensed by Health Canada, and have CE Mark for the treatment of benign pigmented epidermal and cutaneous lesions and treatment of benign cutaneous vascular lesions. The HR650/HR650XL and HR690/HR690XL applicators are cleared by the FDA, licensed by Health Canada, and have CE Mark for the removal of unwanted hair and to effect stable long-term or permanent hair reduction for Fitzpatrick skin types I-IV. The AC Dual applicator is cleared by the FDA, licensed by Health Canada, and has CE Mark for the treatment of acne vulgaris. The DiamondPolar™ and OctiPolar™ applicators on the Venus Versa™ system are cleared by the FDA for non-invasive treatment of moderate to severe facial wrinkles and rhytides on females with Fitzpatrick skin types I-IV. The DiamondPolar™ applicator is licensed by Health Canada and has CE Mark for non-invasive treatment of moderate to severe facial wrinkles and rhytides on females with Fitzpatrick skin types I-IV. The OctiPolar™ applicator on the Venus Versa™ system is licensed by Health Canada and has CE Mark for temporary body contouring via skin tightening, circumferential reduction, and cellulite reduction. The NanoFractional RF™ (Viva) applicator is cleared by the FDA, licensed by Health Canada, and has CE Mark for dermatological procedures requiring ablation and resurfacing of the skin.

**Sensations described by the author, not actual indications.

September 9, 2026
TORONTO, September 9 th , 2026 (GLOBE NEWSWIRE) – Venus Concept Inc. (“Venus Concept” or the “Company”), a global medical aesthetic technology leader, today announced the appointment of Brad Oliver as Chief Executive Officer, effective as of September 7, 2026. He succeeds Rajiv De Silva, who will assume the role of Special Advisor to support a seamless leadership transition. The Board believes that Brad’s commercial leadership experience, strategic vision, and industry expertise position the Company well for its next phase of growth and value creation. Brad brings more than 20 years of leadership experience in the aesthetic industry, most recently as President & General Manager – Americas at Lumenis, and has a proven track record of driving growth globally, operational excellence, and innovation. "I am honored to be appointed Chief Executive Officer of Venus Concept and grateful for the confidence the Board has placed in me,” said Mr. Oliver. “The Company has established a strong foundation under Rajiv's leadership, and I look forward to working closely with him during the transition. Together with our employees, customers, and partners, we will remain focused on disciplined commercial execution, product innovation, profitable growth, and creating long-term value for our customers, employees, and shareholders.” “It has been a pleasure to lead Venus through a transformational time in the organization’s journey,” said Mr. De Silva. “I am grateful for the opportunity to work together with the leadership team, the Board and our partners to grow the business. We have transformed the commercial, operational and financial capabilities of the organization and built a strong foundation for the future. I remain highly confident in the Company’s strategy, pipeline and long-term growth opportunities. I look forward to supporting a smooth transition and watching Venus continue its transformation under Brad’s new leadership.” The Board expresses its gratitude to Rajiv for his leadership and ongoing commitment to the Company. As Special Advisor, Rajiv will work closely with Brad during the transition period to ensure continuity across strategic, operational, and customer-facing initiatives. “On behalf of the Board, I would like to thank Rajiv for his leadership and contributions to the Company and for his support during this transition to ensure a seamless handoff of leadership responsibilities,” said Avinash Amin, M.D., Managing Partner of Madryn Asset Management and Chairman of the Board. “The Board looks forward to Brad’s new leadership of the organization and is confident that his expertise will accelerate commercial efforts globally and the execution of its strategic priorities as the company progresses towards continuing to establish a leadership position in the Medical Device Aesthetics industry.” The leadership transition is not expected to impact the Company’s strategic priorities, customer relationships, employee commitments, or ongoing business operations. Venus Concept remains focused on delivering innovative solutions to its customers, expanding market opportunities, and driving sustainable long-term growth. About Venus Concept Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reaches over 60 countries and 9 direct markets. Venus Concept's product portfolio consists of aesthetic device platforms, including Venus NOVA, Venus Versa, Venus Versa PRO, Venus Bliss, Venus Bliss MAX, Venus Viva, Venus Viva MD, Venus Legacy, Venus Velocity, Venus Epileve and AI.ME. Venus Concept's hair restoration systems include NeoGraft ® and the ARTAS iX ® Robotic Hair Restoration system. Venus Concept is backed by Madryn Asset Management, a leading healthcare investment firm that provides capital to innovative growth-stage healthcare companies offering unique and transformative products and technologies. View Full Article Investor Relations Contact : Damian Yeung, CPA investorrelations@venus.ai
Purple gradient branding graphic for Doublo × Venus Signature Edition
July 28, 2026
TORONTO, July 28, 2026 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”), a global medical aesthetic technology leader, today announced it has entered into an exclusive distribution agreement with HIRONIC Co. Ltd. (“HIRONIC”), a KOSDAQ listed South Korean company specializing in medical aesthetic devices, pursuant to which the Company acquires the exclusive right to distribute HIRONIC’s Doublo 2.0 device in the United States and Canada. The “New Doublo 2.0” is a synergistic, multi-energy-based medical device platform for the face and body, equipped with two separate handpieces that enables clinics to offer customer Cold Plasma and RF microneedling treatments. The device has received 510(k) certification from the U.S. Food and Drug Administration, and the Company intends to make it available to customers in the United States during 2H 2026. Venus Concept will support future regulatory approval efforts in Canada for the device and any additional handpiece technologies for both regions. “HIRONIC is a global leader in developing innovative medical aesthetic technologies and we are excited for the new partnership, starting with the Doublo x Venus Signature Edition,” said Rajiv De Silva, Chief Executive Officer of Venus Concept. “With this device, we look forward to offering our customers an innovative, exclusive Cold Plasma and RF Microneedling platform. By combining these complementary technologies, the platform delivers synergistic effects from the epidermis to the dermis, enabling comprehensive skin rejuvenation by addressing multiple skin concerns and enhancing overall skin revitalization. The Doublo also complements our existing portfolio by enhancing the range of treatment modalities for a customizable treatment plan to address each patient’s skin needs. We aim to expand our partnership in the future to bring to our customers additional new and novel technologies from HIRONIC, once regulatory approvals have been obtained.” About Venus Concept Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reaches over 60 countries and 9 direct markets. Venus Concept's product portfolio consists of aesthetic device platforms, including Venus NOVA, Venus Versa, Venus Versa PRO, Venus Bliss, Venus Bliss MAX, Venus Viva, Venus Viva MD, Venus Legacy, Venus Velocity, Venus Epileve and AI.ME. Venus Concept's hair restoration systems include NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Venus Concept is backed by Madryn Asset Management, a leading healthcare investment firm that provides capital to innovative growth-stage healthcare companies offering unique and transformative products and technologies. Investor Relations Contact: Damian Yeung, CPA investorrelations@venus.ai View Full Article
May 22, 2026
Skin Cancer Awareness Month highlights prevention and early detection. Learn how dermatologists support care with advanced tools and treatments.